|
Colorectal Carcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Bronchiectasis
|
0.110 |
AlteredExpression
|
disease |
BEFREE |
We used whole-exome sequencing to identify compound heterozygous mutations in ARHGEF1, resulting in the loss of ARHGEF1 protein expression in 2 primary antibody-deficient siblings presenting with recurrent severe respiratory tract infections and bronchiectasis.
|
30521495 |
2019 |
|
Bronchiectasis
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
Overall, our data showed that Six1 is essential for the progression of MLL-AF9-induced AML via maintaining the pool of LSC.
|
31050834 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
Here, we used a conditional knockout Hif-1α mouse model together with a standard chemotherapy regimen to evaluate LSC targeting in AML.
|
30595549 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
Hence, CD9 could be a very relevant marker for minimal residual disease (MRD) monitoring in AML based on LSC targeting.
|
30740913 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
METTL14 is required for development and maintenance of AML and self-renewal of leukemia stem/initiation cells (LSCs/LICs).
|
29290617 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
We performed in silico analysis of highly prognostic human AML LSC gene expression signatures using existing datasets of drug-gene interactions to identify compounds predicted to target LSC gene programs.
|
29921955 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
To identify an LSC gene expression signature and test its association with clinical outcomes in AML.
|
21177505 |
2010 |
|
Leukemia, Myelocytic, Acute
|
0.070 |
Biomarker
|
disease |
BEFREE |
The identification of CalDAG-GEF I as a proto-oncogene in BXH-2 acute myeloid leukemia is the first evidence implicating Rap1 signaling in myeloid leukemia.
|
11278453 |
2001 |
|
leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
METTL14 is required for development and maintenance of AML and self-renewal of leukemia stem/initiation cells (LSCs/LICs).
|
29290617 |
2018 |
|
Childhood Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
METTL14 is required for development and maintenance of AML and self-renewal of leukemia stem/initiation cells (LSCs/LICs).
|
29290617 |
2018 |
|
leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
In accordance with our observation that increased expression of miR-126 is associated with unfavorable survival in patients with t(8;21) acute myeloid leukemia (AML), we show that miR-126 overexpression exhibits a stronger effect on long-term survival and progression of AML1-ETO9a-mediated leukemia stem cells/leukemia initiating cells (LSCs/LICs) in mice than does miR-126 knockout.
|
26361793 |
2015 |
|
Childhood Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
In accordance with our observation that increased expression of miR-126 is associated with unfavorable survival in patients with t(8;21) acute myeloid leukemia (AML), we show that miR-126 overexpression exhibits a stronger effect on long-term survival and progression of AML1-ETO9a-mediated leukemia stem cells/leukemia initiating cells (LSCs/LICs) in mice than does miR-126 knockout.
|
26361793 |
2015 |
|
leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
These data strongly support the importance of efficient LSC-targeting for the outcome of patients with leukemia.
|
17339181 |
2007 |
|
Childhood Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
These data strongly support the importance of efficient LSC-targeting for the outcome of patients with leukemia.
|
17339181 |
2007 |
|
leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
However, it is not known which, if any, of these RGS-rhoGEFs (LARG (leukemia-associated rhoGEF), p115rhoGEF, or PDZrhoGEF) plays a role in G protein-coupled receptor-stimulated rho signaling.
|
15143072 |
2004 |
|
Childhood Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
However, it is not known which, if any, of these RGS-rhoGEFs (LARG (leukemia-associated rhoGEF), p115rhoGEF, or PDZrhoGEF) plays a role in G protein-coupled receptor-stimulated rho signaling.
|
15143072 |
2004 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Results demonstrated that ARHGEF1 (GEF1), ARHGEF2 (GEF2), and K-RAS genes are the targets of miR-143. miR-143 expression significantly decreased mRNA and protein levels of GEF1, GEF2, and K-RAS genes; lowered the constitutive activities of RhoA, Rac1, and Cdc42 GTPases; decreased the protein levels of MMP-2 and MMP-9; but significantly increased the protein level of E-cadherin. miR-143 expression also significantly inhibited the migration and invasion of Panc-1 cells in vitro, liver metastasis, and xenograft tumor growth in vivo.
|
23070684 |
2012 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
These data highlight control of the Rap GEF1-Rap1 molecular switch as a specific requirement for PLCgamma1-mediated tumour cell adhesion.
|
18037957 |
2008 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
DNA measurement by LSC revealed DNA diploidy in 14 tumors and DNA aneuploidy in 24 tumors.
|
10769720 |
2000 |
|
Childhood Acute Myeloid Leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
By fitting a Cox-LASSO regression model to the clinical outcome and gene-expression levels of LSC enriched genes in 163 pediatric participants of the AML02 multi-center clinical trial (NCT00136084), we developed a six-gene LSC score of prognostic value in pediatric AML (pLSC6).
|
31645648 |
2020 |
|
Childhood Acute Myeloid Leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Although pediatric and adult AML represent two genetically very distinct diseases, we reasoned that common LSC gene expression programs are shared and consequently, the highly prognostic LSC17 signature score recently developed in adults may also be of clinical interest in childhood AML.
|
30089916 |
2019 |
|
Neoplasm, Residual
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Hence, CD9 could be a very relevant marker for minimal residual disease (MRD) monitoring in AML based on LSC targeting.
|
30740913 |
2019 |